Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
Newcastle University
Procurement Services, Kingsgate
Newcastle
NE1 7RU
UK
Contact person: Mrs Natalie Morton
Telephone: +44 1912086396
E-mail: natalie.morton@ncl.ac.uk
NUTS: UKC
Internet address(es)
Main address: www.ncl.ac.uk
Address of the buyer profile: www.ncl.ac.uk
I.1) Name and addresses
Durham University
The Palatine Centre, Stockton Road
Durham
UK
E-mail: Edwin.e.milligan@durham.ac.uk
NUTS: UKC
Internet address(es)
Main address: https://www.durham.ac.uk
I.1) Name and addresses
Northumbria University Newcastle
Newcastle
NE1 1XE
UK
E-mail: Hugh.Rhodes@northumbria.ac.uk
NUTS: UK
Internet address(es)
Main address: https://northumbria.ac.uk
I.1) Name and addresses
University of Sunderland
Sunderland
UK
E-mail: Cheryl.Holmstrom@sunderland.ac.uk
NUTS: UK
Internet address(es)
Main address: https://Sunderland.ac.uk
I.2) Joint procurement
The contract involves joint procurement
The contract is awarded by a central purchasing body
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Education
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
(NU1433-10) RAR-M Therapeutics Ltd: The Provision of Business Consultancy to Assist Commercialisation of University Research
Reference number: DN473477
II.1.2) Main CPV code
79400000
II.1.3) Type of contract
Services
II.1.4) Short description
Amyotrophic lateral sclerosis (ALS) — as with most other neurodegenerative diseases, including Alzheimer's and Parkinson’s — is a major medical challenge and is having an ever-increasing impact upon the lives of patients, carers and indeed of society as a whole. Scientists at Durham (Chemistry Department) and Aberdeen Universities have recently designed, synthesised and identified a lead drug candidate with the potential for establishing a new treatment approach for ALS and with a longer-term potential of being effective for other neurodegenerative diseases.
The technology is now being patented and we are ready to develop a commercial vehicle to drive the drug development programme forwards and raise the necessary investment required for the next stages. The need for an experienced Business Executive/CEO, who has already delivered drugs to the market in the neurodegenerative area, is essential to support the commercial team and especially the CEO directly. Although two of the team have commercial (spinout) experience (e.g. as CTO of LightOx who are successfully raising second phase major investment currently for LightOx), the successful launch of market leading drugs and the raising of the finance to make that happen is needed to successfully take the company forward.
In the longer term (such as Phase III raise of ca. GBP 100+ million), such an executive might well be appointed as CEO, but in these early development stages, advise and business support is required.
II.1.6) Information about lots
This contract is divided into lots:
No
II.1.7) Total value of the procurement
Value excluding VAT:
30 000.00
GBP
II.2) Description
II.2.3) Place of performance
NUTS code:
UKC
II.2.4) Description of the procurement
Newcastle, Durham, Sunderland and Northumbria universities, in common with universities throughout the UK, have advanced relevant systems and procedures and also dedicate significant public resource to both research and commercialisation of that research. A key route to commercialisation is the creation of a new business (a spin-out company) wherein the intellectual property (IPR) developed exclusively licensed to a university start-up company in exchange for (founders) shares in that company.
The universities ill engage suitably qualified and experienced executives through the DPS as and when required over the DPS period. The specific requirements will be detailed in each further competition.
The initial brief of the executive for which he/she will be paid, dependent upon the scope of the specific project engagement sought, either a payment or a combination of a payment and a share/stock option will typically be to:
(a) produce a viable business plan;
(b) obtain university approval for the venture;
(c) act for the company in the spin-out legal process and address all the company formation matters;
(d) provide to the appropriate university all matters necessary for ESIF, ERDF and Research England reporting requirements;
(e) secure (venture capital and/or other) funding in accordance with the business plan.
II.2.5) Award criteria
Quality criterion: Quality
/ Weighting: 70
Cost criterion: Price
/ Weighting: 30
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
Yes
II.2.14) Additional information
The Northern Accelerator brand is supported by Research England which is responsible for funding, engaging with and understanding English higher education institutions (HEIs).The Connecting Capability Fund (CCF) supports university collaboration in research commercialisation.
The Northern Accelerator programme is also supported by a European Regional Development Fund (ERDF) project that supports the commercialisation of university research, also delivered under the Northern Accelerator brand.
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Restricted procedure
IV.1.3) Information about a framework agreement or a dynamic purchasing system
A dynamic purchasing system was set up
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2019/S 009-016574
Section V: Award of contract
Contract No: NU1433-10
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
22/04/2020
V.2.2) Information about tenders
Number of tenders received: 2
Number of tenders received from SMEs: 2
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 0
Number of tenders received by electronic means: 2
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
DyoDelta Biosciences Ltd
Greater London
UK
NUTS: UKC
The contractor is an SME:
Yes
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 30 000.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.4) Procedures for review
VI.4.1) Review body
Newcastle University
Tyne and Wear
NE1 7RU
UK
VI.4.2) Body responsible for mediation procedures
Newcastle University
Tyne and Wear
UK
VI.4.3) Review procedure
Precise information on deadline(s) for review procedures:
Newcastle University has incorporated a minimum 10 calendar day standstill period at the point information on the award of the contract was communicated to tenderers. This period allowed unsuccessful tenderers to see further debriefing before the contract was entered into. Such additional information would be requested from the address referred to in Part 1.1 above. If an appeal regarding the award contract has not been successfully resolved, the Public contracts Regulations 2015 provide for aggrieved parties who have been harmed or are at risk of harm by breach of the rules to take action in the high court (England, Wales and Northern Ireland). Any such action must be brought promptly. Where a contract has not been entered into the court may order the setting aside of the award decision in order for the authority to amend any document and may award damages. If the contract has been entered into court may only award damages.
VI.4.4) Service from which information about the review procedure may be obtained
Newcastle University
Tyne and Wear
UK
VI.5) Date of dispatch of this notice
19/05/2020